Replies to post #133641 on Biotech Values

[iwfal]

MNTA -

A single substitutable FoB is guaranteed to make good money as long as the corresponding branded drug continues to sell well.

Given the much lower % sales dollars flowing to Momenta (than for Copaxone) apparently big pharma and Momenta either:

1) Disagree with your assertion above

OR

2) Don't think Momenta will be sole substitutible

OR

3) Don't think Momenta will get fully substitutible at all and will thus be just one of the multitudes of non-subs biosimilars.